Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results
August 09, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
XTX101, tumor-selective anti-CTLA-4, has successfully reached dose levels exceeding the target dose with limited active (unmasked) molecule in the periphery in ongoing Phase 1 clinical trial ...
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
June 16, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
Paul Clancy Elected as Chair of the Board of Directors Robert Ross, M.D., Appointed to Board of Directors WALTHAM, Mass., June 16, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO),...
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
May 17, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
May 12, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022 On track with plans to submit IND for...
Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference
April 07, 2022 06:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 06:30 ET
|
Xilio Therapeutics, Inc.
Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022 On Track with Plans to Submit IND for XTX301 in Second Half of 2022 Continue to Anticipate Cash Runway...
Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference
February 28, 2022 06:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day
February 03, 2022 06:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer,...
Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors
January 20, 2022 07:30 ET
|
Xilio Therapeutics, Inc.
WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with...